Stock News

State Street Cut By $1.75 Million Its Biomarin Pharmaceutical (BMRN) Position; Société Générale Société anonyme (SCGLY) Had 3 Bullish Analysts

Société Générale Société anonyme (OTCMKTS:SCGLY) Logo

State Street Corp decreased Biomarin Pharmaceutical Inc (BMRN) stake by 0.49% reported in 2017Q4 SEC filing. State Street Corp sold 19,693 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 13.73%. The State Street Corp holds 3.99M shares with $356.21 million value, down from 4.01M last quarter. Biomarin Pharmaceutical Inc now has $14.90 billion valuation. The stock increased 2.36% or $1.95 during the last trading session, reaching $84.64. About 397,244 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since April 17, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

Among 5 analysts covering Societe Generale SA (OTCMKTS:SCGLY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Societe Generale SA had 7 analyst reports since August 7, 2015 according to SRatingsIntel. Morgan Stanley upgraded Société Générale Société anonyme (OTCMKTS:SCGLY) on Tuesday, December 6 to “Overweight” rating. The firm earned “Neutral” rating on Tuesday, September 22 by JP Morgan. On Thursday, November 10 the stock rating was upgraded by JP Morgan to “Overweight”. J.P. Morgan downgraded the shares of SCGLY in report on Thursday, January 18 to “Hold” rating. The rating was upgraded by HSBC on Tuesday, September 29 to “Buy”. The firm has “Hold” rating by Zacks given on Friday, August 7. The rating was downgraded by Societe Generale to “Neutral” on Tuesday, September 22. See Société Générale Société anonyme (OTCMKTS:SCGLY) latest ratings:

18/01/2018 Broker: J.P. Morgan Rating: Hold Downgrade

Societe Generale Group provides financial services in Europe and internationally. The company has market cap of $44.34 billion. It operates through three divisions: French Retail Banking, International Retail Banking & Financial Services, and Global Banking and Investor Solutions. It has a 15.26 P/E ratio. The firm offers retail banking services to individual customers, professionals, and corporate and non-profit clients under the Societe Generale, Crédit du Nord, and Boursorama brands; and international retail banking and consumer credit services to individual customers, professionals, corporates, institutions, and associations in Europe, Russia, Africa, and French overseas departments and territories.

The stock increased 0.99% or $0.1085 during the last trading session, reaching $11.0285. About 93,748 shares traded. Société Générale Société anonyme (OTCMKTS:SCGLY) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Since December 14, 2017, it had 0 insider buys, and 16 insider sales for $11.20 million activity. 15,000 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares with value of $1.25 million were sold by BIENAIME JEAN JACQUES. Shares for $333,150 were sold by LAWLIS V BRYAN on Tuesday, January 2. 3,818 shares were sold by Davis George Eric, worth $320,254 on Friday, March 16. $169,774 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by Ajer Jeffrey Robert. Shares for $1.34M were sold by FUCHS HENRY J. 800 shares were sold by HERON ELAINE J, worth $71,116.

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical had 86 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Outperform” rating by BMO Capital Markets on Friday, October 27. RBC Capital Markets maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, February 26 with “Outperform” rating. As per Friday, July 21, the company rating was maintained by BMO Capital Markets. The firm earned “Buy” rating on Monday, March 12 by Wedbush. The firm earned “Conviction Buy” rating on Monday, March 7 by Goldman Sachs. William Blair maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Wednesday, August 5. William Blair has “Buy” rating and $160 target. The rating was maintained by Oppenheimer with “Perform” on Tuesday, February 23. The stock has “Outperform” rating by Raymond James on Tuesday, September 1. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Jefferies on Monday, September 25. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Neutral” rating by Piper Jaffray on Monday, November 7.

State Street Corp increased Sensient Technologies Corp (NYSE:SXT) stake by 125,926 shares to 1.61 million valued at $117.80M in 2017Q4. It also upped Stag Industrial Inc (NYSE:STAG) stake by 182,174 shares and now owns 2.14M shares. Getty Realty Corp (NYSE:GTY) was raised too.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *